Reduce time and costs during the physical testing phases of drug delivery devices
In recent years, organizations such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have been encouraging companies to replace, reduce, and refine animal studies. In parallel, the cruelty-free label has soared in popularity as people seek to make a difference through their purchasing choices. At Dassault Systèmes, our technology pairs perfectly with this movement by changing testing paradigms from physical to virtual in all phases including bench test, animal testing, and clinical trial; a shift that yields significant time savings. Where the physical approach can take years before reaching clinical trial, a virtual-first approach enables a representative clinical trial simulation in a matter of days. This results in lower overall costs, higher accuracy, and significantly reduced dependency on controversial animal testing.
Our solution utilizes modeling and simulation approaches in an effort to create virtual twins of not only the drug delivery devices, but the patients as well. These models can be representative of test subjects in several drug development experiments and are instrumental in reducing time and costs during physical testing phases.
Learn about how virtual twins can enable pharmaceutical and/or device companies to:
